Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data

  • Acadia Pharmaceuticals Inc ACAD stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated's VRTX non-opioid painkiller.
  • The company scrapped the ACP-044 program after evaluating the final phase 2 data on bunion removal patients. 
  • Initial data announced in April showed that the primary endpoint of pain intensity was not met.
  • Rival Vertex boasted a mid-phase win for a similar candidate.
  • Acadia has also discontinued ACP-319, which was tested in combination with Calquence in a phase 1 trial in relapsed/refractory chronic lymphocytic leukemia.
  • In Acadia's earnings report, the company hopes that trofinetide, submitted last month to the FDA for approval, will become the first treatment for a rare neurological condition called Rett syndrome.
  • It also pointed to an in-house molecule called ACP-204, which is in phase 1 trials for neuropsychiatric indications. Acadia aims for ACP-204 to build upon its learnings garnered from the neuropsychiatric drug Nuplazid, the company's only approved therapy to date.
  • Price Action: ACAD shares are down 3.76% at $16.00 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!